Vir Biotechnology (VIR) Enterprise Value (2019 - 2026)

Vir Biotechnology has reported Enterprise Value for 9 years, with the latest figure at -$205.2 million in Q1 2026.

• Quarterly Enterprise Value rose 66.12% year-over-year to -$205.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$205.2 million (up 66.12% YoY) and the FY2025 annual result came in at -$238.3 million, up 68.95% from the prior year.
• Enterprise Value rose to -$205.2 million in Q1 2026 per VIR's latest filing, from -$238.3 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$205.2 million in Q1 2026 and troughed at -$2.3 billion in Q3 2022.
• A 5-year average of -$1.0 billion and a median of -$998.5 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value slumped 2269.96% in 2022, then jumped 83.57% in 2024.
• Over 5 years, Enterprise Value stood at -$1.5 billion in 2022, then increased by 1.41% to -$1.5 billion in 2023, then surged by 49.26% to -$767.4 million in 2024, then jumped by 68.95% to -$238.3 million in 2025, then increased by 13.89% to -$205.2 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$205.2 million, -$238.3 million, and -$330.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.